Pwc Fifth Annual National Congress on Health Care Compliance Pharmaceutical Sales and Marketing: Are You Afraid to Look Under the Rocks? Michael P. Swiatocha.

Slides:



Advertisements
Similar presentations
AGENDA My Pharma Career: Joan K. Snyder The Pharmaceutical Industry
Advertisements

4.02 Compliance Training Brian A. Dahl Senior Counsel Takeda Pharmaceuticals North America, Inc. November 14, 2003.
Introduction to Existing State Disclosure Laws and Regulations Summit on Disclosure, Transparency and Aggregate Spend For Drug, Device and Biotech Companies.
Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
Pharmaceutical Congress Spring 2003 Preconference Symposia Compliance 101 for Pharmaceutical Manufacturers Michael P. Swiatocha June 8, 2003.
Professional Education Support Wyeth Pharmaceuticals Melinda Somasekhar, PhD.
PwC Medical Device Compliance Survey Discussion of Survey Results.
CME 101 The Application Process Sponsored by the Office of Continuing Medical Education.
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
Pharmaceutical Compliance Current Trends: Hot Button Issues to Look at this Year in Sales, Marketing, Clinical, Medical Affairs and Government Pricing.
Marketing to Doctors – Payments for Loyalty Julie Brill Assistant Attorney General Vermont Attorney General ’ s Office Montpelier,
2010 Region II Conference Corporate Compliance Panel June 3, 2010
Compliance and Fraud & Abuse: An Investors Perspective February 2002 Andy Bressler, Managing Director, Industry Research Group.
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas.
Revenue Cycle Management Medical Technology Acquisition and Assessment Team Members: Joseph Dixon, Michael Morotti, Mari Pirie-St. Pierre, David Robbins.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
Role of Industry in Clinical Care, Research and Education Rev 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
VCU School of Medicine Policy on Industry Relations Effective July 1, 2009.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
© 2008 Foley Hoag LLP. All Rights Reserved. 1 The New Massachusetts Pharmaceutical & Medical Device Marketing Regulations How to Address and Overcome Likely.
New Staff Orientation: Industry Relations Emory School of Medicine Zainab R. Wurie, JD July 15, 2014.
Impact Health NDAC Meeting Stewart Levy R.Ph. January 14, 2005.
Fourth Annual Medical Research Summit Concurrent Session 4.05 – Managing CROs and SMOs from a Compliance Perspective Michael SwiatochaAprill 23, 2004.
How to Develop Internal Monitoring Programs SEVENTH ANNUAL PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS AND BEST PRACTICES FORUM Stephen F. Mohr Global.
SCHERING-PLOUGH INTERNATIONAL Building an International Compliance Program An Operational Approach Dalton Smart CPA, MBA Schering-Plough International.
Pitfalls and Lessons Learned: Advanced Implementation Strategies for a Compliant Grant Process National CME Audioconference December 9, 2008.
SHRM Survey Findings: An Examination of How Social Media is Embedded in Business Strategy and Operations ©SHRM 2011 January 2012 SHRM Survey Findings:
1 Strategies for a Compliant Grant Process CIA Monitoring Obligations A. Monica Jonhart Director-U S Pharmaceuticals Compliance Bristol-Myers Squibb.
Best Practices: Financial Resource Management February 2011.
Because your patients come first. Regulatory and Practice Management Services Daniel L. Johnson, CPC, CPC-H.
Key Compliance Risks in Clinical Trials Kathleen Meriwether Principal, ERNST & YOUNG, LLP Fraud Investigation & Dispute Services.
1 Investigating Fraud & Abuse Violations in Medical Research Janet Rehnquist, Esq. Venable LLP th Street, NW Washington, DC
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
Pre-Conference III: Auditing, Monitoring and Effective Internal Investigations Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
KEY ENFORCEMENT ISSUES - The Government's Perspective Kathleen Meriwether Assistant United States Attorney Eastern District of Pennsylvania UNITED STATES.
PwC Medical Device Compliance Survey Discussion of Survey Results March 30, 2006.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
Connecting the Dots A Practical Approach to Integrating Compliance, Risk and Quality Jody Ann Noon RN, JD Partner Health Care Regulatory Practice.
Pharmaceutical Regulatory and Compliance Congress Special Pre-Conference Workshop: HHS OIG Model Compliance Guidance November 13, 2002.
+ Role of Industry in Clinical Care, Research, and Education.
EFPIA and IFPMA Code Compliance Strategies Richard BERGSTRÖM Chair, EFPIA Code Steering Committee Chair, IFPMA Code Compliance Network Presentation at.
1 Continuing Medical Education and Industry Sponsorship The Pharma, Biotech and Device Colloquium Princeton, NJ June 7, 2005 Julie K. Taitsman, M.D., J.D.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
Copyright © Harvard Medical School. All Rights Reserved. Outside Activity Report: What Do I Need to Report?
Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Special Program for Internal/Compliance Audit Professionals: Enterprise Risk.
Agenda for Session Compliance in Clinical Research
Session 1.01 US Healthcare Professionals Abroad – Issues and Practical Solutions Caroline West – Senior VP, Chief Compliance and Risk Officer Shire Pharmaceuticals.
1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.
ROPES & GRAY LLP The Compliance Environment and Grant Process: Oversight and Response in the Pharmaceutical Industry Howard L. Dorfman December 9, 2008.
PwC National disclosure audio conference: Analysis of the revised Physician Payments Sunshine Act and state drug marketing laws February 10, 2009 “Where.
Building A Pharmaceutical Compliance Program Presentation to the Sixth Annual Congress on Health Care Compliance February 7, 2003 Janice Toran Fujisawa.
Overview of Huron and the International Medical Device Compliance Code Compendium The Second Annual Medical Device Regulatory, Reimbursement and Compliance.
Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,
FDA Regulatory and Compliance Symposium Industry Collaboration & Interactions with Health Professionals: Can Conflicts of Interest be Properly Managed?
0 Due Diligence Monitoring and Auditing of Third Party Vendors October 28, 2008 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
Compliance at the Crossroads: How can the Compliance Profession Move to the Second Generation? A Practical Approach to Integrating Compliance, Risk and.
November | 1 CONTINUING CARE COUNCIL Report to Forum Year
Fourth Annual Pharmaceutical Regulatory and Compliance Congress Preconference I A Compliance Primer for the Pharmaceutical Sector Michael P. Swiatocha.
1 The Implementation of Fair Market Value What can we learn from recent enforcement actions? Debjit Ghosh Life Sciences Advisory Services Huron Consulting.
II Volga specialized forum "Medicine. Pharmacy"
Risk Management: why and how to protect your health center
Lilly Grant Funding Disclosure May 27, 2008
An Introduction to the Sunshine Act
California’s “Comprehensive Compliance Program” Law
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
Benchmarking Compliance for the Healthcare Industry
RIBGH 2019 Healthcare Summit Kim Keck President & CEO
Presentation transcript:

Pwc Fifth Annual National Congress on Health Care Compliance Pharmaceutical Sales and Marketing: Are You Afraid to Look Under the Rocks? Michael P. Swiatocha February 8, 2002

PWC National Congress on Health Care Compliance 02/08/02 1 Agenda Introduction - The US Pharmaceutical Industry What’s Under the Rocks?  Compliance Program Structure  Sales and Marketing Activities Assessment Methodology Q & A

PWC Introduction

PWC National Congress on Health Care Compliance 02/08/02 3 US Pharmaceutical Industry Strategies for Revenue Growth  Invest in R&D  Discover and develop new and innovative products  Develop new indications and line extensions  Form alliances  Improve productivity and reduce costs  Increase share of voice in the marketplace  Design and execute innovative programs in: Marketing Sales Customer Education

PWC National Congress on Health Care Compliance 02/08/02 4 US Pharmaceutical Industry Strategies for Revenue Growth  Invest in R&D  Discover and develop new and innovative products  Develop new indications and line extensions  Form alliances  Improve productivity and reduce costs  Increase share of voice in the marketplace  Design and execute innovative programs in: Marketing Sales Customer Education

PWC National Congress on Health Care Compliance 02/08/02 5 US Pharmaceutical Industry Accelerated Growth of US Sales Reps: 1994 to 2000 Number of Representatives (000) Sources: Scott-Levin, Pharmaceutical Representative and WR Hambrecht + Co Estimates, 2001

PWC National Congress on Health Care Compliance 02/08/02 6 US Pharmaceutical Industry Source: PhRMA Industry Profile, 2001 Overall Growth in Pharmaceutical Marketing Expenditures: ~ 16% Per Year

PWC National Congress on Health Care Compliance 02/08/02 7 US Pharmaceutical Industry  Rx Sales $61 billion $138 billion  Marketing Spend on MDs $5.5 billion $13.2 billion  Professional Spending in 2000 Samples - $ 7.9 billion Office-based promotion - $4.0 billion Hospital-based promotion - $770 million Sources: Scott-Levin, IMS, MedAd News, Pharmaceutical Representative and Datamonitor Plc

PWC National Congress on Health Care Compliance 02/08/02 8 US Pharmaceutical Industry  Detailing remains the primary marketing tool  Current marketplace estimates: 78,000 sales representatives (2X 1995) US sales force size – 20 to 8000 representatives/managers 600,000 targeted physicians (static) 390,000 physicians see sales representatives $ per detail Additional targets: - Nurse practitioners - Physician’s assistants Sources: Scott-Levin, Pharmaceutical Representative, US Census Bureau, MedAd News and Datamonitor Plc

PWC National Congress on Health Care Compliance 02/08/02 9 US Pharmaceutical Industry  Shrinking access to physicians in offices 1995 – 12 minutes (average time spent with sales representatives) 2000 – 7 minutes (average time spent with sales representatives)  Improve sales force ROI Increase access to customers Entertainment-based programs - meetings and events - dinner programs Meals for office staff Gifts and business courtesies Sources: Scott-Levin, Pharmaceutical Representative, US Census Bureau and Datamonitor Plc

PWC What’s under the rocks?

PWC National Congress on Health Care Compliance 02/08/02 11 What’s under the rocks? Perspective for the Discussion  Fraud and Abuse  Anti-Kickback  False Claims  FDA  HIPAA

PWC National Congress on Health Care Compliance 02/08/02 12 What’s under the rocks? Compliance Program Structure  Compliance officer and committee  Written policies and procedures (including specific policies for customer activities, clinical research, consultants, grants, etc.)  Education and training  Internal reporting  Auditing  Compliance-related disciplinary policies  Reporting of potential misconduct

PWC National Congress on Health Care Compliance 02/08/02 13 What’s under the rocks? Sales and Marketing Activities  Entertainment, meals and gifts  Consulting, speaking and advisory fees  Continuing medical education  Off-label usage  Pharmaceutical samples and free goods  Partnerships  Fees for detailing  e-Business

PWC National Congress on Health Care Compliance 02/08/02 14 What’s under the rocks? Entertainment, Meals and Gifts  2000 – $1.9 billion for meetings with customers  2000 – 314,000 events  Control Standards AMA Guidelines - Company policies and SOPs Training and communication Monitoring - initial approval - expense report - corrective action

PWC National Congress on Health Care Compliance 02/08/02 15 What’s under the rocks? Entertainment, Meals and Gifts (continued)  Examples of industry practices: Strict adherence to AMA guidelines Annual company-wide $ limit per physician for all entertainment, meals and gifts (multiple divisions) No annual $ limit per physician (maximum $ limit per event) Spouse/guest permitted (yes/no) Spouse/guest expense included in $ limit or 2X $ limit Annual company-wide $ limit per physician for medical textbooks (multiple divisions) Guidelines for F/T and P/T government employees $ limit per occasion for business courtesies

PWC National Congress on Health Care Compliance 02/08/02 16 What’s under the rocks? Consultants, Speakers and Advisory Boards  Control Standards AMA Guidelines Company policies and SOPs Training and communication Written contract signed by both parties Services are necessary and legitimate HHS OIG’s List of Excluded Individuals and Entities Monitoring - aggregate compensation to individuals - FMV of payments

PWC National Congress on Health Care Compliance 02/08/02 17 What’s under the rocks? Consultants, Speakers and Advisory Boards (continued)  Examples of Industry Practices Managed by headquarters only Managed at regional and district levels Formal approval process (medical, legal, etc.) Payment ranges based on specific criteria and FMV Reimbursement for travel expense Incidental meals Entertainment (yes/no)

PWC National Congress on Health Care Compliance 02/08/02 18 What’s under the rocks? Consultants, Speakers and Advisory Boards (continued)  Issues to Consider Thought leaders and product advocates - critical to product launch - long-term relationships (consulting retainers) - clinical trials - publications - speaker programs - aggregate compensation - potential conflict of interest (P&T decision-maker)

PWC National Congress on Health Care Compliance 02/08/02 19 What’s under the rocks? Continuing Medical Education  Accredited and non-accredited programs  Control Standards AMA Guidelines Accreditation Council for Continuing Medical Education (ACCME) Guidelines Company policies,SOPs, and training Written agreement signed by both parties Monitoring - initial approval - documentation (before/after) - audit third party activity

PWC National Congress on Health Care Compliance 02/08/02 20 What’s under the rocks? Continuing Medical Education (continued)  Examples of Industry Practices Managed at headquarters and regional levels Limited to CME accredited programs (yes/no) Non-CME managed through grants and contributions Formal approval and tracking processes Entertainment, meals and gifts subject to other policies No unrestricted grants for educational programs

PWC National Congress on Health Care Compliance 02/08/02 21 What’s under the rocks? Continuing Medical Education (continued)  Issues to Consider Inducements for purchase or recommendation for use of product Targeting of participants Program agenda and content Venue Vendor management Application of policy to other providers

PWC National Congress on Health Care Compliance 02/08/02 22 What’s under the rocks? Off-label Usage of Pharmaceuticals  Cost of new product development  Access to patients for clinical trials  Control Standards FDAMA “safe harbor” Company policies, SOPs, training and communication Management process to handle unsolicited requests Monitoring - approval process for sales promotions - customer targeting and call reporting - grants for studies and publications

PWC National Congress on Health Care Compliance 02/08/02 23 What’s under the rocks? Off-label Usage of Pharmaceuticals (continued)  Examples of Industry Practices Managers and representatives trained by legal Strong disciplinary policy Restricted to medical liaisons, specialty representatives and medical affairs Strict guidelines for sales representatives Documentation of requests from customers and responses

PWC National Congress on Health Care Compliance 02/08/02 24 What’s under the rocks? Off-label Usage of Pharmaceuticals (continued)  Issues to Consider Business plans Incentive compensation programs Thought leader and opinion leader use Support for advocacy groups Product websites – cross-border visits

PWC National Congress on Health Care Compliance 02/08/02 25 What’s under the rocks? Pharmaceutical Samples and Free Goods  $7.9 billion for samples  Cost of doing business  Control Standards PDMA requirements Company policies, SOPs, training and communication Records and reports Monitoring - high utilization - audits - corrective action

PWC National Congress on Health Care Compliance 02/08/02 26 What’s under the rocks? Pharmaceutical Samples and Free Goods (continued)  Examples of Industry Practices Strong internal/external management program Hardcopy/automated process Disciplinary policy Vouchers and coupons E-requests

PWC National Congress on Health Care Compliance 02/08/02 27 What’s under the rocks? Pharmaceutical Samples and Free Goods (continued)  Issues to Consider Patient assistance programs FMV for drug delivery devices, laboratory equipment, etc. Phase IV supplies Vendors

PWC National Congress on Health Care Compliance 02/08/02 28 What’s under the rocks? Other Rocks  Partnerships  Fees for Detailing  e-Detailing

PWC Assessment Methodology

PWC National Congress on Health Care Compliance 02/08/02 30 Assessment Methodology Five Step Process Phase I Step 1 Step 2 Step 3Step 4Step 5 Initial Information Acquisition Shelf Document Review Senior Management Interviews Contract Reviews (Optional) Initial Review of Policies, Processes and Controls Company Operating Guidelines Other Relevant Documents Targeted Review of Controls Over Key Activities Additional Interviews Assessment of Processes/Controls Gap Analysis Options for Process Improvements Gaps in Compliance Controls Options for Improvements Design of On-going Monitoring Process Baseline Assessments of Businesses Initial Profile of Processes and Controls Over Customer Activities List of Priority Activities for Phase II Output of Steps 1 and 2 Phase II Management Update Steering Committee Project Team Legal Counsel

PWC Q & A

PWC National Congress on Health Care Compliance 02/08/02 32 For Further Information PricewaterhouseCoopers LLP Michael Swiatocha